LABIANA

Trading sesion


29/05/2024 Close

2.2800

Last price


16.46 mill. €

Capitalisation

3.64

Dif.(%)


82.40

% Year 2024

Last Trade

Date

29/05/2024

Hour

Close

Last

2.2800

Ref.

2.2000

Dif.(%)

3.64

Volume (Shares)

8,234

Turnover (€x1000)

18.49

X
29/05/2024 17:37:09
BidAsk
OrdersVolumePricePriceVolumeOrders
12502.24002.28003,2632

Security

Security name

LABIANA HEALTH

Ticker

LAB

ISIN

ES0105638003

NIF

A-87992616

Shares Admitted

7.221.255

Nominal

0,1 Euros

Capital Admitted

722.125,50 Euros

Trading

Continuo

Liquidity Provider

GVC GAESCO VALORES, S.V., S.A.

Registered Advisor

VGM ADVISORY PARTNERS, S.L.U.

Auditor

BDO AUDITORES, S.L.

Address

EUROPA 34, POZUELO DE ALARCON , MADRID

Contact

investors@labiana.com

Historical Summary

 202220232024 until 29/05

Capital Admitted (thousands of euros)

722722722

Shares (x 1,000)

7,2217,2217,221

Period Close Price (euros)

3.36001.25002.2800

Period Last Price (euros)

3.36001.20002.2800

Period High Price (euros)

4.95003.46002.3000

Period Low Price (euros)

2.92001.05001.1800

Capitalisation (thousands of euros)

24,2639,02716,464

Volume (thousands of shares)

187484290

Turnover (thousands of euros)

786843453

"We are a company committed to innovation in order to provide society with products of the highest quality that improve and favor the conditions of people and the care of animals and our environment."

Company Profile

Since its foundation in 1958 as a company specialized in the manufacture of products for veterinary use, the Group has undergone a continuous process of growth, diversification and internationalization, becoming today a pharmaceutical group of animal and human health reference, which stands out as:

  • Manufacturer of a broad catalog of proprietary generic products for animal and human health, among which Fosfomycin Trometamol (generic antibiotic for urinary tract infections) stands out in human health.
  • CDMO (Contract Development and Manufacturing Organization), which provides services for third parties in the development and manufacture of drugs in a wide variety of presentations, specializing in sterile, lyophilized and biological pharmaceutical forms.

Currently, Labiana has 4 operating companies, 464 employees, 6 manufacturing plants (Serbia and Spain) with the capacity to absorb the expected growth, a portfolio of its own drugs with more than 50 products marketed in more than 150 countries and more than 300 customers, all leading national and international pharmaceutical groups, including several multinationals with which it has a relationship of more than 15 years.

From 1980 until 1999, Labiana was part of the BASF Group and became BASF LABIANA, a period during which it developed vitamin injectables that made it one of the leading manufacturers of injectables for animal health in Europe, a position it still holds.

Its vocation for service and the conviction that animal and human health are interdependent and linked to the ecosystems in which they coexist, led it in 2002 to incorporate the human health pharmaceutical division and since then it has continued to grow with a focus on the 'One health/Una sola salud' principle.

With this same philosophy, in 2019 it incorporated the Serbian Veterinarski Zavod Subotica into the Group, which has opened the door to the high value-added segment of biologics (vaccines) in the field of animal health, enabling it to complete its product portfolio and provide a broader service to its customers.

Additionally, the company acquired in Turkey Zoleant Pharmaceuticals International also in 2019, which allows it to expand its own product portfolio and access new markets. Finally, the company launched its companion animal division, LabianaPets, in 2019, broadening the product commercialization focus.

Inside Information

Other Relevant Information

Financial Reports

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.